AtriCure, Inc. (ATRC)
AtriCure, Inc. (ATRC)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 108 | 1,756 | -267 | -12,937 |
| Share-based compensation expense | 11,273 | 11,260 | 12,424 | 21,001 |
| Amortization of investments | NaN | 0 | 0 | 0 |
| Acquired in-process research and development expense | NaN | 1,000 | 0 | 5,000 |
| Loss on debt extinguishment | NaN | 0 | 0 | 0 |
| Depreciation | 2,889 | 2,997 | 3,059 | 6,034 |
| Amortization of intangible assets | 2,384 | 2,110 | 2,110 | 4,221 |
| Amortization of deferred financing costs | 105 | 119 | 120 | 239 |
| Other non-cash adjustments | 708 | 648 | 415 | 311 |
| Accounts receivable | 5,019 | 3,755 | -2,989 | 4,844 |
| Inventories | 2,770 | -455 | 2,637 | 74 |
| Other current assets | 5,163 | -1,359 | 205 | 1,482 |
| Accounts payable | 5,572 | -1,275 | 360 | -45 |
| Accrued liabilities | -13,508 | 3,705 | 9,124 | -5,832 |
| Other noncurrent assets and liabilities | 575 | 352 | 776 | 1,001 |
| Net cash used in operating activities | -3,996 | 20,027 | 26,716 | 10,591 |
| Proceeds from sale of property and equipment | NaN | 0 | 0 | 0 |
| Sales and maturities of available-for-sale securities | NaN | 0 | 0 | 0 |
| Purchases of property and equipment | 3,852 | 1,602 | 2,605 | 4,843 |
| Acquisitions, including in-process research and development | NaN | 1,000 | 0 | 5,000 |
| Proceeds from capital grant | 0 | 0 | 0 | 500 |
| Net cash used in investing activities | -3,852 | -2,602 | -2,605 | -9,343 |
| Proceeds from revolving credit facility, net of financing costs | NaN | 0 | 0 | 0 |
| Payments on debt, leases and financing obligation | 1,194 | 321 | 301 | 579 |
| Proceeds from financing obligation | NaN | 0 | 6,250 | NaN |
| Payment of financing costs | 777 | 0 | 0 | 0 |
| Proceeds from stock option exercises | NaN | 1,367 | NaN | NaN |
| Shares repurchased for payment of taxes on stock awards | 11,442 | 228 | 357 | 10,578 |
| Proceeds from issuance of common stock under employee stock purchase plan | NaN | 5,923 | NaN | NaN |
| Proceeds from stock option exercises | -4,485 | NaN | 392 | 4,251 |
| Net cash used in financing activities | -13,255 | 2,098 | 5,984 | -6,906 |
| Effect of exchange rate changes on cash and cash equivalents | -160 | 40 | -26 | 733 |
| Net decrease in cash and cash equivalents | -21,263 | 19,563 | 30,069 | -4,925 |
| Cash and cash equivalentsbeginning of period | 167,428 | -25,144 | 122,721 | NaN |
| Cash and cash equivalentsend of period | 146,165 | 19,563 | 147,865 | NaN |